Susquehanna International Group
HELX icon

Susquehanna International Group’s Franklin Genomic Advancements ETF HELX Stock Holding History

Susquehanna International Group’s Portfolio HELX Stock Details HELX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,934
Closed -$227K – 12513
2024
Q1 		$227K Sell
6,934
-582
-8% -$18.2K ﹤0.01% 10333
2023
Q4 		$229K Buy
+7,516
New +$209K ﹤0.01% 10395

Other funds holding HELX

GT
Glenview Trust Louisville, Kentucky $6.37B AUM 23.72% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's HELX Position: Q2 2024 in Review

Susquehanna International Group sold out of Franklin Genomic Advancements ETF (HELX) in Q2 2024, closing a stake of 6,934 shares — an estimated $227K sold.

Susquehanna International Group first reported a position in HELX in Q4 2023 and held it in 2 quarters. The position peaked at $229K in Q4 2023. 7 funds tracked by Wall St. Rank hold HELX as of Q2 2024.

  • Susquehanna International Group reported no remaining Franklin Genomic Advancements ETF position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 6,934 Franklin Genomic Advancements ETF shares in Q2 2024, an estimated $227K.
  • Susquehanna International Group first reported a position in Franklin Genomic Advancements ETF in Q4 2023 and held it in 2 quarters.
  • Susquehanna International Group's Franklin Genomic Advancements ETF position peaked at $229K in Q4 2023.
  • 7 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.